Topical Allstate and Nasal Allergen Challenge
Phase 3
Withdrawn
- Conditions
- Allergic Rhinitis
- Registration Number
- NCT01231724
- Lead Sponsor
- University of Chicago
- Brief Summary
The purpose of this study is to see whether Allstate Nasal Spray when given in the nose is safe and can reduce the signs and symptoms of allergic rhinitis (hayfever).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method Number of sneezes and total nasal symptom score (TNSS) (sum of nasal stuffiness, nasal discharge, and nasal itching) (scale 0-3 for each symptom; total score 0-9) are co-primary endpoints. 10 minutes following each nasal challenge
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does Allstate Nasal Spray utilize to reduce allergic rhinitis symptoms?
How does the efficacy of Allstate Nasal Spray compare to standard-of-care antihistamines in allergic rhinitis?
Are there specific biomarkers that correlate with improved outcomes in patients using Allstate Nasal Spray?
What adverse events were observed in NCT01231724 and how were they managed in clinical practice?
What are the potential advantages of Allstate Nasal Spray over corticosteroid-based nasal therapies for allergic rhinitis?
Trial Locations
- Locations (1)
University of Chicago
🇺🇸Chicago, Illinois, United States
University of Chicago🇺🇸Chicago, Illinois, United States